Table 2.

Tumor response to treatment in each treatment group

	Anti-PD-1 plus chemotherapy (n = 38)	Anti-PD-1 monotherapy (n = 20)	Chemotherapy (n = 19)
Objective response, n (%; 95% CI)	13 (34.2%; 21.6–48.8)	0	1 (5.3%; 0.3–22.6)
Disease control rate, n (%; 95% CI)	34 (89.5%; 77.5–96.3)	13 (65%; 44.2–82.3)	9 (47.4%; 27.4–68.0)
Best overall response, n (%)
Complete response	3 (7.9%)	0	0
Partial response	10 (26.3%)	0	1 (5.3%)
Stable disease	21 (55.3%)	13 (65%)	8 (42.1%)
Progressive disease	4 (10.5%)	7 (35%)	10 (52.6%)